Science Highlights
Published on December 23, 2025
Belumosudil versus combination therapy for steroid-refractory cGVHD
Raju G, Walji M, Nemirovsky D, et al. Real-World Experience of Belumosudil and Belumosudil/Ruxolitinib Combination in Steroid-Refractory Chronic Graft-Versus-Host Disease. Bone Marrow Transplantation. 2025; (doi; 10.1038/s41409-025-02721-z).
Findings from a real-world study affirm belumosudil as a promising option for patients with chronic graft-versus-host disease and inadequate response to at least two prior lines of therapy. The retrospective analysis included 67 participants with steroid-refractory or steroid-dependent disease, treated either with belumosudil monotherapy or a combination of belumosudil plus ruxolitinib. A robust treatment response was observed across the board, with a median failure-free survival rate of 75% at 6 months and 67% at 12 months—outcomes that dovetailed with clinical trial results. Researchers reported deeper responses in patients who continued active therapy beyond the 6-month treatment mark. Those who received belumosudil and ruxolitinib together had similar 6- and 12-month responses. The combination treatment was well-tolerated, with a low incidence of drug-related toxicities categorized at grade 3 or higher.
Read More
![]()